FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep